• Research type

    Research Study

  • Full title

    The UK Interstitial Lung Disease Long-COVID19 study (UKILD-Long COVID): understanding the burden of Interstitial Lung Disease in Long COVID



  • Contact name

    M E Weeks

  • Contact email

  • Sponsor organisation

    Imperial College London,

  • ISRCTN Number


  • Identifier


  • Identifier

    NA, NA

  • Duration of Study in the UK

    1 years, 3 months, 0 days

  • Research summary

    A commonly reported after effect of contracting COVID-19 is developing Post COVID Interstitial Lung Disease (PC-ILD). PC-ILD is inflammation, scarring (fibrosis), or both that can cause permanent lung damage. Inflammation may be reversible but can progress to fibrosis which may worsen over time. The number of people with ILD not clear but could be high. Highlighting the disease history and risk factors for development of lung fibrosis could help define better treatment options.
    This will be a longitudinal observational study of patients with suspected ILD following COVID-19, to determine the prevalence of ILD at 12 months following infection as well as factors that influence the recovery or worsening of the condition.
    Patients with a proven COVID infection who have continued to suffer respiratory symptoms prompting further clinical care and a CT scan to determine their lung condition.
    CT imaging and lung function testing will be performed as part of routine investigation in the post-COVID clinic. For patients who consent to additional tests, these will be done by a member of the research team at the same clinic.
    Following assessment of post COVID patients at baseline (3-6 months post infection), those with clinical and radiological features suggestive of ILD will be included into the study population. A repeat CT will be offered at 12 months (+/- 3 months) post infection. Those with no clinical, radiological or physiological features of ILD will be invited to enrol as part of the control cohort. Participants will also be offered lung function testing at 3 and 12 months and asked to complete questionnaires assessing for breathlessness, fatigue, cognition and quality of life. They will be offered the opportunity to perform a walk test to assess aerobic capacity and further blood tests for genetic testing and further analysis.

  • REC name

    London - Riverside Research Ethics Committee

  • REC reference


  • Date of REC Opinion

    10 Aug 2021

  • REC opinion

    Favourable Opinion